Providing Fuel for Startups Since 2008

Please read our investment criteria before applying.

NTAN accepts applications from entrepreneurial companies seeking funding that are domiciled in the U.S.

NTAN typically invests in companies within the SaaS, Fintech, B2B & B2C technology, CPG, health care and services industries.

The following categories do not meet our investment criteria: venture funds, ventures with a large real estate component, television or radio programs, film, theater or art productions, non-profit organizations and companies domiciled outside of the U.S.

We do not fund companies using the 506(c) exemption, Reg CF (Crowdfunding) or investments subject to a broker/dealer fee. Companies that previously used the 506(c) exemption or Reg CF (Crowdfunding) must agree to self-certification of accredited status by our investors.

Key NTAN investment criteria that startups should consider before applying for funding:

• NTAN has invested in companies with an average valuation of $ 8.7M - valuations in the range of $3M to $20M.
• A capable management team with domain expertise
• A scalable business model
• An addressable market of at least $500 million
• Limited capital expenditure requirements
• Opportunities that can be accelerated with support from our investors
• A product or service in beta (versus alpha) stage of development that has been created with input from clients or potential clients
• “Proof of concept” revenue or significant pilots - except for health care bio/pharma, diagnostics and devices companies
• A plausible exit strategy within 5-8 years that will bring a potential 10X return on investment
• CPG (Consumer Products) - NTAN investors look for a minimum of $500K in annual revenue.
• Health Care (bio/pharma, diagnostics and devices), additional investment considerations include:
• Protectable intellectual property, with protection underway or granted
• A concept based on verifiable science that validates approach and supports expectation of efficacy
• Articulated pathways, with projected timing, for regulatory and reimbursement approvals (if applicable)